This Viewpoint from the National Institutes of Health describes a new set of guidelines for the conduct and registration of clinical trials in the United States.
This Viewpoint proposes that institutional review boards play a larger role in ensuring timely public reporting of clinical trial results, with the goals of promoting medical innovation, reducing publication bias, and maximizing the value of clinical trials.
In this Viewpoint, JoAnn Manson and colleagues discuss the risk of postrandomization “confounding,” a bias that can be introduced in long-duration trials of sustained interventions, using statin initiation after randomization in Women’s Health Initiative trials as an example.
This JAMA Guide to Statistics and Methods discusses how to interpret the results of clinical trials that are stopped early based on formal, prespecified stopping rules.
This study characterizes trends in the total number of clinical trials and in the proportion of trials funded by the National Institutes of Health and registered at ClinicalTrials.gov between 2006 and 2014.
This Guide to Statistics and Methods describes the reasons for conducting a noninferiority trial and how to analyze and interpret the results from a trial that did.
This Guide to Statistics and Methods describes the reasons for using cluster randomization in a clinical trial and how to analyze and interpret the results from a trial that did.
This Viewpoint discusses the use of platform trials for efficient evaluation of multiple treatments.
This Viewpoint advocates initiating greater transparency in reporting results of clinical trials as a responsibility that will benefit the health of many.
This prospective economic evaluation reports that use of LMW heparin for venous thromboembolism prophylaxis in critically ill patients was more effective than unfractionated heparin, with similar or lower costs.
This randomized clinical trial assesses the effectiveness of dexmedetomidine when added to standard care in patients with agitated delirium receiving mechanical ventilation.
Boughey and coauthors determine the false-negative rate for sentinel lymph node (SLN) surgery following chemotherapy in 663 women initially presenting with biopsy-proven node-positive breast cancer. In an Editorial, Morrow and Dang discuss false-negative rates and their role in determining whether to use more aggressive therapies.